ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost XR), ACHIEVES PRIMARY EFFICACY ENDPOINT IN PHASE 2A GLAUCOMA CLINICAL TRIAL
RESEARCH TRIANGLE PARK, NC – OCTOBER 6, 2015 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company’s lead product candidate, ENV515 (travoprost XR). In this phase 2a trial, ENV515 achieved its primary efficacy endpoint by demonstrating a statistically significant and clinically meaningful reduction in intraocular pressure (IOP) with results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution).
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.